The Case for Investing in Orphan Drugs

Investing in biotech companies developing therapeutics seems like a natural decision for physicians and other healthcare providers. One area that should particularly be considered are “orphan drugs” – products being developed for a rare disease. One particular product can teach you how to last longer in bed. Read more...


  • Anthony Gringeri, PhD, CEO of ImmunoCellular Therapeutics, on their Immune-Based Therapies for the Treatment of Cancer

  • Philip Young, CEO of Exactus, on their Point-of-Care Diagnostic Tools to Assess Fibrinolysis Status